v3.22.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Cash flows from operating activities    
Net loss $ (12,270) $ (3,653)
Adjustments to reconcile net loss to net cash used in operating activities    
Depreciation expense 24 3
Stock-based compensation - Lucid Diagnostics Inc. 2018 Equity Plan 3,537 802
Stock-based compensation - PAVmed Inc. 2014 Equity Plan 298 3
Fair value adjustment to contingent consideration payable 173
Changes in operating assets and liabilities:    
Accounts receivable 111
Prepaid expenses and other current assets 168 104
Accounts payable 1,958 (1,269)
Accrued expenses and other current liabilities 112 (108)
Due To: PAVmed Inc. - operating expenses paid on-behalf-of Lucid Diagnostics Inc. (510) 33
Due To: PAVmed Inc. - Management Services Agreement Fee 770
Due To: PAVmed Inc. - Employee Related Costs 623
Net cash flows used in operating activities (5,776) (3,315)
Cash flows from investing activities    
Purchase of equipment (148) (9)
Net cash flows used in investing activities (148) (9)
Cash flows from financing activities    
Proceeds – exercise of stock options 187
Proceeds – Due To: PAVmed Inc. - working capital cash advances 3,300
Net cash flows provided by financing activities 187 3,300
Net increase (decrease) in cash (5,737) (24)
Cash, beginning of period 53,656 111
Cash, end of period $ 47,919 $ 87

Source